Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer
Recruiting in Palo Alto (17 mi)
+233 other locations
Age: 18+
Sex: Male
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 3
Waitlist Available
Sponsor: Abbott
No Placebo Group
Pivotal Trial (Near Approval)
Prior Safety Data
Trial Summary
What is the purpose of this trial?
This study is being done to evaluate the safety and efficacy of atrasentan in men with non-metastatic hormone-refractory prostate cancer.
Research Team
GG
Gary Gordon, M.D.
Principal Investigator
Abbott
Eligibility Criteria
Inclusion Criteria
Have been diagnosed with prostate cancer.
Have a rising PSA while on hormone therapy or following surgical castration.
Treatment Details
Interventions
- Atrasentan (Endothelin Receptor Antagonist)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Abbott
Lead Sponsor
Trials
760
Recruited
489,000+
Dr. Etahn Korngold
Abbott
Chief Medical Officer
MD, Harvard Medical School
Robert B. Ford
Abbott
Chief Executive Officer since 2020
Bachelor's degree from Boston College, MBA from UC Berkeley, Haas School of Business